DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 197 filers reported holding DENALI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,060,524 | -30.1% | 99,880 | 0.0% | 0.04% | -27.6% |
Q2 2023 | $2,947,459 | +28.1% | 99,880 | 0.0% | 0.06% | +11.5% |
Q1 2023 | $2,301,235 | -17.2% | 99,880 | 0.0% | 0.05% | -20.0% |
Q4 2022 | $2,777,663 | -9.4% | 99,880 | 0.0% | 0.06% | -19.8% |
Q3 2022 | $3,065,000 | +4.3% | 99,880 | 0.0% | 0.08% | +14.1% |
Q2 2022 | $2,939,000 | -8.5% | 99,880 | 0.0% | 0.07% | +1.4% |
Q1 2022 | $3,213,000 | -27.9% | 99,880 | 0.0% | 0.07% | -27.1% |
Q4 2021 | $4,455,000 | -11.7% | 99,880 | -0.1% | 0.10% | -17.9% |
Q3 2021 | $5,045,000 | -16.7% | 100,000 | +29.5% | 0.12% | -16.4% |
Q2 2021 | $6,056,000 | +86.1% | 77,200 | +35.4% | 0.14% | +57.3% |
Q1 2021 | $3,255,000 | +159.2% | 57,000 | +280.0% | 0.09% | +111.9% |
Q4 2020 | $1,256,000 | – | 15,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |